Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: J Theor Biol. 2016 Jan 27;394:197–211. doi: 10.1016/j.jtbi.2016.01.026

Fig. 4.

Fig. 4.

Dynamics of anti-tumor CD4+ helper T cells and of pro-tumor regulatory T cells when synergy between an anti-angiogenic treatment and a DC treatment is achieved. A standard anti-VEGF treatment was started on day 600 and was followed by a standard DC treatment started on day 710. Since regulatory T cells are stimulated by licensed DC, the number of Tregs initially increases following unlicensed DC treatment. However, this type of immunotherapy also activates helper T cells and CTL that target the tumor. The activation of anti-tumor cells outweighs the activation of pro-tumor cells. Hence, the end result is complete tumor elimination. (A) number of inactive helper T cells, (B) number of active helper T cells, (C) number of inactive Tregs, and (D) number of active Tregs.